Bio-Techne Corporation TECH
NASDAQ · Healthcare · Biotechnology
$72.67
Close on Fri, 20 Nov 2026 · market value $11.4B
What the price is betting on
Priced for a lot to go rightAt $73, the price assumes revenue grows about 20% a year for five years, from $1.2B to about $2.9B by FY2031. That is about twice what analysts expect for the next two years and about eight times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 9.9% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than TECH? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$33
Base
$39
Bull
$47
Today $73
- Bear $33. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $39. Cash flow grows 8% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $47. Cash flow grows 11% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2027$1.4B$1.3B, below the path
- FY2028$1.7B$1.4B, below the path
- FY2029$2B$1.6B, below the path
- FY2030$2.4B$1.7B, below the path
- FY2031$2.9B$2B, below the path
Each year's revenue at 20% growth from $1.2B in the 12 months to September 2026.
At a glance
Healthcare · Biotechnology · listed on NASDAQ
- Revenue, FY2026
- $1.2B
- Growth, 3 years a year
- 2.4%
- Cash margin
- 22%
- Net debt
- $24.4M
- Shares, 3-year change
- −3%
- Dividend yield
- 0.4%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.